AP-1-Targeted Anti-Inflammatory Activities of the Nanostructured, Self-Assembling S5 Peptide

Figure 1

Effects of the S5 peptide on TNF-α and PGE₂ production and viability of LPS-treated RAW264.7 cells and BM-derived macrophages. (a, b, and c) The levels of NO, PGE₂, and TNF-α in the supernatants of RAW264.7 cells or bone marrow-derived macrophages that had been treated with the S5 peptide (0 to 100 μg/mL) or standard compounds (prednisolone and indomethacin) in the presence or absence of LPS (1 μg/mL) for 6 (TNF-α) or 24 (PGE₂) h were analyzed by EIA and ELISA, respectively. (d) The viability of RAW264.7 cells and BW-derived macrophages was determined by the MTT assay. and compared with control cells; compared with normal cells.

(a)

(b)

(c)

(d)